Pramlintide

Summary

Pramlintide (Symlin) is an injectable amylin analogue approved as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved desired glucose control. It reduces postprandial hyperglycemia by slowing gastric emptying, suppressing inappropriate glucagon secretion, and inducing satiety.

Mechanism of Action

Synthetic analogue of human amylin that acts as a pancreatic hormone replacement. Activates amylin receptors in the area postrema and hypothalamus to suppress post-meal glucagon secretion, slow gastric emptying, and promote satiety, thereby reducing postprandial glucose excursions.

Routes of Administration

Goals & Uses

• Weight managementBody CompositionModerate
• HbA1c reductionGlycemic ManagementHigh
• Satiety inductionAppetite RegulationModerate
• Glucagon suppressionGlycemic ManagementHigh
• Postprandial glucose controlGlycemic ManagementHigh

Contraindications

• Hypersensitivity to pramlintide or excipientsImmunologicalHigh
• Poor adherence to insulin regimenBehavioralModerate
• Confirmed gastroparesisGastrointestinalHigh
• Hypoglycemia unawarenessEndocrine/MetabolicHigh

Adverse Effects

• Severe hypoglycemiaEndocrine/MetabolicUncommon
• Injection site reactionsLocalUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents
• AnorexiaMetabolicCommon

Drug Interactions

• Insulin (mealtime)High
• Alpha-glucosidase inhibitors (e.g., acarbose)Moderate
• Oral medications requiring rapid GI absorption (e.g., analgesics, antibiotics)Moderate
• Anticholinergic agentsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patients (<18 years)AgeRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionUnapprovedNot approved by the European Medicines Agency (EMA); not marketed in the EU.
• United StatesApprovedApproved: Adjunct to mealtime insulin in type 1 diabetes mellitus in adults, Adjunct to mealtime insulin in type 2 diabetes mellitus in adultsApproved by FDA March 2005. Boxed warning for severe insulin-induced hypoglycemia. Available as Symlin and SymlinPen prefilled pen devices.
• United KingdomUnapprovedNot approved by the MHRA for use in the United Kingdom.

Approved by the FDA in March 2005. Carries a boxed warning regarding risk of severe hypoglycemia, especially when used with insulin. Requires reduction in mealtime insulin dose at initiation.

Evidence & Sources

No sources recorded yet.